Kidney Cancer

Retrospective trial results inform utility of tivozanib in the real-world treatment of renal cell carcinoma.

Better health-related quality of life outcomes were associated with nivolumab and cabozantinib for advanced renal cell carcinoma vs sunitinib.

A surrogate for toxicity and drug exposure, cabozantinib dose reductions were tied to longer durations of time to treatment failure and overall survival for patients with metastatic renal cell carcinoma.

Treatment with cabozantinib in the second line yielded responses in patients with advanced renal cell carcinoma who received immunotherapy in the frontline, regardless of prior regimen.

Subgroups analysis from the CLEAR trial of lenvatinib plus pembrolizumab showed efficacy results were consistent between East Asian patients and the overall study population.

Data presented at 2022 ASCO GU of front nivolumab plus cabozantinib for renal cell carcinoma show persistent overall survival benefit versus sunitinib.

New findings indicate that treatment with cabozantinib following failure of immunotherapy proved to be safe and feasible in metastatic renal cell carcinoma.

Rates of progression-free survival at 3- and 4-year landmarks significantly improved with tivozanib vs sorafenib for relapsed or refractory RCC.

Data from the TITAN-RCC trial presented at 2022 ASCO GU showed that certain immune cell–related parameters may be predictive of response to nivolumab/ipilimumab in advanced or metastatic clear cell renal cell carcinoma

Chung-Han Lee, MD, PhD, spoke about using biomarkers to help predict responses in patients with metastatic renal cell carcinoma treated on the KEYNOTE-146 study.

Research suggests patients with advanced renal cell carcinoma who received neoadjuvant cabozantinib saw reductions in tumor size with no disease progression.

Patients with previously treated metastatic urothelial carcinoma or renal cell carcinoma experienced promising benefit from treatment with niraparib and cabozantinib.

In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.

The new drug application for dovitinib as a third-line treatment for patients with renal cell carcinoma is supported by a pre-marketing approval for companion diagnostic, Dovitinib-DRP.

A longer treatment-free survival was seen in patients with advanced renal cell carcinoma who were treated with first-line nivolumab and ipilimumab compared with sunitinib.

A panel of experts reflect on how to treat patients with advanced renal cell carcinoma by reviewing clinical trial data and discussing patient cases.

Drs Orenstein and Braun close out the program by examining unmet needs in the advanced renal cell carcinoma treatment space, as well as emerging options.

A panel of experts explain what they do within their clinical practices to select second- or later-line therapies for patients with advanced renal cell carcinoma.

Dr Braun closes out the clinical trial dialogue by discussing the CONTACT-03 and Tivo-3 trials.

Patient Case 2 continues, and Drs Zhang and Orenstein discuss second-line trials for advanced renal cell carcinoma.

Dr Choueiri presents the second patient case to the panel: a 53-year-old woman with renal cell carcinoma that underwent a nephrectomy.

Dr Orenstein details how he manages quality of life for patients with advanced renal cell carcinoma.

The phase 2 MK-6482-004 trial found that belzutifan produced positive response data for patients with renal cell carcinoma and non–renal cell carcinoma neoplasms associated with von Hippel-Lindau disease.

The panel continues their conversation about the first patient case.

Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.

Patients with advanced renal cell carcinoma who received first-line nivolumab and ipilimumab experienced an improved treatment-free survival vs sunitinib.

In a systemic review assessing the use of first-line post-protocol immunotherapy for patients with kidney cell carcinoma, investigators reported that use was low in randomized clinical trials among patients in the control group.

David A. Braun, MD, PhD continues the first-line clinical trial discussion with the addition of KEYNOTE-426 and CLEAR trial data.

Tian Zhang, MD, MHS, and Moshe Orenstein, MD, MA, recall data from two clinical trials for first-line treatment of advanced renal cell carcinoma: CheckMate-9ER and CheckMate-214.

Patients with intermediate-risk and high-risk renal cell carcinoma had a statistically significant improvement in disease-free survival after being treated with pembrolizumab, which was approved by the FDA.